Pharmaceutical company Morepen Laboratories has unveiled a bold expansion blueprint aimed at significantly scaling its domestic formulations business. The firm plans to onboard over 1,000 medical representatives over the next three years, with 200 additions slated for FY26 alone, in an effort to penetrate deeper into both urban and rural markets. With its formulations division currently generating Rs. 325 crore, Morepen aims to grow this figure to Rs. 1,000 crore within five years. This strategy aligns with the company’s broader vision to capture a larger share of India’s Rs. 2.38 lakh crore pharmaceutical market, which is on track to reach USD 130 billion by 2030.
Aggressive Workforce Expansion to Drive Growth
In a strategic push to bolster its domestic footprint, Morepen Laboratories announced plans to recruit over 1,000 medical representatives within the next three years. This expansion will begin with the addition of more than 200 team members in FY26, representing a clear commitment to intensify its engagement with doctors, pharmacies, and healthcare institutions across India. “This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market,” said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. By significantly increasing its field force, the company aims to improve brand visibility, prescription-driven sales, and direct interaction with medical professionals—key pillars in building sustainable long-term growth in the pharmaceutical sector.
Targeting Rs. 1,000 Crore in Formulations Revenue
Currently, Morepen’s formulations segment contributes Rs. 325 crore in revenue. The company has set an ambitious target of tripling this figure to Rs. 1,000 crore within five years, supported by a multi-pronged strategy involving workforce scaling, deeper market penetration, and new product introductions. This initiative is not merely about volume expansion, but also about improving gross margins and shareholder returns. The company anticipates that enhanced operational scale and broader geographical coverage will result in higher-margin revenue streams, particularly in high-growth therapeutic areas.
Capturing a Larger Share of India’s Expanding Pharma Market
The Indian pharmaceutical sector is currently valued at Rs. 2.38 lakh crore, with projections suggesting it could touch USD 130 billion by 2030, growing at an estimated compound annual growth rate (CAGR) of 8.2%. Morepen aims to position itself strategically within this rapidly expanding ecosystem by leveraging low-cost manufacturing efficiencies, introducing cost-competitive formulations, and extending its presence across Tier-II, Tier-III cities, and rural geographies. The company believes this ground-level network expansion will help it tap underserved markets, offering not just scale, but market resilience in an increasingly competitive pharmaceutical environment.
Product Innovation and Competitive Pricing as Growth Catalysts
Morepen has indicated that its growth will be further bolstered by new product launches, many of which are already under production at highly competitive costs. These formulations are expected to offer value propositions across a range of chronic and acute therapies—an essential strategy given the increasing demand for affordable healthcare in India. This manufacturing edge, combined with targeted marketing and field support, will help the company to differentiate itself in a crowded marketplace.
Market Response and Stock Performance
Investors have responded positively to the company’s forward-looking vision. On the BSE, Morepen shares rose 3.84% to trade at Rs. 49.97 apiece, reflecting market optimism about the company’s renewed growth trajectory and strategic clarity. This upward momentum suggests a recalibration of investor sentiment, as the firm shifts from a stable operator to a growth-focused pharmaceutical contender within the domestic market.
Conclusion: A Strategic Pivot Toward Market Leadership
Morepen Laboratories’ plan to triple its formulations business underscores a deliberate pivot toward aggressive, organic expansion in India's pharmaceutical landscape. By investing in human capital, operational scale, and new product development, the company is aligning itself with broader industry trends while also creating avenues for enhanced profitability and market leadership. As India’s healthcare needs evolve, and access to affordable medication becomes more critical, Morepen’s strategy to build grassroots medical networks and deliver high-quality formulations at scale could position it as a formidable force in the country’s pharmaceutical future.
Comments